LIfT Biosciences
June 18, 2025
Company Presentation
Cell and Gene Therapy and Genome Editing
153C
LIfT BioSciences is a UK and Ireland-based biotech pioneering the world’s first neutrophil-based cell therapy platform, N-LIfT. This allogeneic platform produces Immuno-Modulatory Alpha Neutrophils (IMANs) from hematopoietic and induced pluripotent stem cells. IMANs exhibit a dual mechanism: directly killing cancer cells and reprogramming the tumor microenvironment to activate the immune system, offering durable responses in solid tumors. Founded by Alex Blyth in 2016 after his mother's death from pancreatic cancer, LIfT aims to overcome treatment resistance and tumor escape. The company is advancing its first-generation HSC-derived IMANs into clinical trials and developing scalable iPSC-derived CAR-IMANs for broader applications. With offices in London, Galway, and Boston, and collaborations with pharmaceutical partners, LIfT is committed to delivering affordable, off-the-shelf immunotherapies to patients worldwide
Company HQ City:
London
Company HQ State:
London
Company HQ Country:
United Kingdom
Year Founded:
2016
Lead Product in Development:
LIfT BioSciences' lead product in development is N-LIfT (Neutrophil Only Leukocyte Infusion Therapy), an allogeneic cell therapy platform that utilizes Immuno-Modulatory Alpha Neutrophils (IMANs) to target and eliminate solid tumors. These IMANs are engineered from hematopoietic stem cells (HSCs) of donors with exceptional innate cancer-killing capabilities. They exhibit a dual mechanism of action: directly destroying cancer cells and modulating the tumor microenvironment to activate the patient's immune system, thereby enhancing the overall anti-tumor response.
Building upon this, LIfT is advancing a second-generation product, CAR-iN-LIfT, which involves genetically modifying IMANs with Chimeric Antigen Receptors (CARs) to enhance their specificity and potency against tumor cells. This approach aims to provide a scalable, off-the-shelf therapy capable of addressing a broad range of solid tumors.
liftbiosciences.com
The company is preparing for clinical trials of N-LIfT, with a Phase I study anticipated to commence in the near future. These trials will assess the safety and efficacy of IMANs in patients with various solid tumors, including pancreatic, lung, and gastric cancers.
CEO
The Chief Executive Officer (CEO) of LIfT BioSciences is Alex Blyth.
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
LIfT BioSciences is currently a preclinical-stage biotechnology company. As such, it does not have any licensed products on the market. The company is developing its lead candidate, N-LIfT (Neutrophil Only Leukocyte Infusion Therapy), which utilizes Immuno-Modulatory Alpha Neutrophils (IMANs) for the treatment of solid tumors. Clinical trials are anticipated to commence in the near future
When you expect your next catalyst update?
LIfT BioSciences' next significant value inflection point is the initiation of its first-in-human clinical trial for N-LIfT (Neutrophil Only Leukocyte Infusion Therapy), anticipated to commence in the near future. This Phase I Investigator-Initiated Trial, conducted in collaboration with the University of Galway, aims to evaluate the safety, tolerability, and immunological activity of Immuno-Modulatory Alpha Neutrophils (IMANs) in patients with solid tumors.
The company has recently achieved several milestones to support this transition into clinical development:
Manufacturing Partnership: LIfT has partnered with Minaris Regenerative Medicine to develop a Good Manufacturing Practice (GMP)-compliant process for producing N-LIfT, ensuring the quality and scalability of the therapy for clinical use.
globenewswire.com
Funding: In September 2024, LIfT secured £10 million in the first close of its Series A financing round, with a second close scheduled for Q1 2025. These funds are allocated to advance IMANs into clinical trials and further develop the N-LIfT platform.
Preclinical Data: Recent presentations at the International Society for Cell and Gene Therapy (ISCT) Annual Meeting highlighted the dual anti-tumor mechanisms of IMANs, combining direct cytotoxic activity with immunomodulation of the tumor microenvironment.
What is your next catalyst (value inflection) update?
LIfT BioSciences anticipates its next major catalyst update in Q3 2025, with the initiation of its first-in-human Phase I clinical trial for its lead cell therapy, N-LIfT (Neutrophil Only Leukocyte Infusion Therapy). This trial, conducted in partnership with the University of Galway and Hooke Bio, aims to evaluate the safety, tolerability, and immunological activity of Immuno-Modulatory Alpha Neutrophils (IMANs) in patients with solid tumors.
The company has made significant strides in preparing for this clinical milestone, including the expansion of its manufacturing and clinical operations into Ireland and securing £10 million in the first close of its Series A financing round.
Website
www.liftbiosciences.com
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}